Evidence map›Paper›PMID 26572643›Full record

ArticlePharmaceutical research2016

Multivariate Analysis of Effects of Asthmatic Patient Respiratory Profiles on the In Vitro Performance of a Reservoir Multidose and a Capsule-Based Dry Powder Inhaler.

Francesca Buttini, Irene Pasquali, Gaetano Brambilla, Diego Copelli, Massimiliano Dagli Alberi, Anna Giulia Balducci, Ruggero Bettini, Viviana Sisti

Abstract read
In one paragraph

Article in Pharmaceutical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Francesca ButtiniDepartment of Pharmacy, University of Parma, Viale delle Scienze 27/A, 43124, Parma, Italy. francesca.buttini@unipr.it.
Irene PasqualiChiesi Farmaceutici SpA, Via Palermo 26, 43122, Parma, Italy.
Gaetano BrambillaChiesi Farmaceutici SpA, Via Palermo 26, 43122, Parma, Italy.
Diego CopelliChiesi Farmaceutici SpA, Via Palermo 26, 43122, Parma, Italy.
Massimiliano Dagli AlberiChiesi Farmaceutici SpA, Via Palermo 26, 43122, Parma, Italy.
Anna Giulia BalducciInterdepartmental Center, Biopharmanet-TEC, University of Parma, Viale delle Scienze 27/A, 43124, Parma, Italy.
Ruggero BettiniDepartment of Pharmacy, University of Parma, Viale delle Scienze 27/A, 43124, Parma, Italy.
Viviana SistiChiesi Farmaceutici SpA, Via Palermo 26, 43122, Parma, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this work was to evaluate the effect of two different dry powder inhalers, of the NGI induction port and Alberta throat and of the actual inspiratory profiles of asthmatic patients on in-vitro drug inhalation performances.

methodsThe two devices considered were a reservoir multidose and a capsule-based inhaler. The formulation used to test the inhalers was a combination of formoterol fumarate and beclomethasone dipropionate. A breath simulator was used to mimic inhalatory patterns previously determined in vivo. A multivariate approach was adopted to estimate the significance of the effect of the investigated variables in the explored domain.

resultsBreath simulator was a useful tool to mimic in vitro the in vivo inspiratory profiles of asthmatic patients. The type of throat coupled with the impactor did not affect the aerodynamic distribution of the investigated formulation. However, the type of inhaler and inspiratory profiles affected the respirable dose of drugs.

conclusionsThe multivariate statistical approach demonstrated that the multidose inhaler, released efficiently a high fine particle mass independently from the inspiratory profiles adopted. Differently, the single dose capsule inhaler, showed a significant decrease of fine particle mass of both drugs when the device was activated using the minimum inspiratory volume (592 mL).

Indexed as

Administration, InhalationAdolescentAdultAgedAnti-Asthmatic AgentsAsthmaBeclomethasoneCapsulesChemistry, PharmaceuticalDry Powder InhalersFemaleFormoterol FumarateHumansInspiratory CapacityMaleMiddle AgedAnti-Asthmatic AgentsBeclomethasoneCapsulesFormoterol FumaratePowdersAlberta throatBreath simulatorMultivariate analysisNEXThaler®RS01

Identifiers

PMID26572643
PMCPMC4744254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.